Exploratory study of NS 065/NCNP 01 in Duchenne muscular dystrophy

Trial Profile

Exploratory study of NS 065/NCNP 01 in Duchenne muscular dystrophy

Completed
Phase of Trial: Phase I

Latest Information Update: 17 May 2016

At a glance

  • Drugs NS 065 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Mar 2015 Status changed from active, no longer recruiting to completed, as reported in a Nippon Shinyaku media release.
    • 04 Sep 2014 Planned End Date changed from 1 Nov 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top